NX-2127
NX-2127-001
Phase 1 small_molecule active
Quick answer
NX-2127 for Chronic Lymphocytic Leukemia (CLL) is a Phase 1 program (small_molecule) at Nurix Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Nurix Therapeutics
- Indication
- Chronic Lymphocytic Leukemia (CLL)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active